Skip to main content

Market Overview

Gene Therapy Player Vera Therapeutics Prices IPO Well Below Range At $11/Share

Gene Therapy Player Vera Therapeutics Prices IPO Well Below Range At $11/Share
  • Vera Therapeutics Inc has priced its 4.35 million share IPO at $11 per share, well below its targeted range of $14 to $16, raising $47.58 million in gross proceeds. The biotech will start trading on NASDAQ from Monday under the ticker “VERA.”
  • Vera’s lead candidate atacicept is a fusion protein to treat IgA nephropathy that recently went through Phase 2a trials.
  • IgAN, also known as Berger’s disease, can lead to inflammatory tissue damage and kidney failure.
  • In its initial S-1 filing seeking as much as $86.25 million, Vera said it would use between $30 million and $35 million to complete its Phase 2b trials, and another $15 million to $20 million to initiate a Phase 2b or Phase 3 trial for patients with lupus nephritis.
  • The company said the proceeds would be able to fund operations for the next 18 months.
  • In 2009, the drug was licensed to Merck KGaA (OTCMKTS: MKGAF), but most of the trials came up short to treat multiple sclerosis, lupus, and rheumatoid arthritis.
  • Last November, shortly after the German pharma announced the successful Phase IIa data for patients with IgAN, Vera licensed the drug for a 10% equity stake and about $733 million in milestones.

Related Articles (MKGAF + MKKGY)

View Comments and Join the Discussion!

Posted-In: Berger's disease BriefsBiotech News Health Care Offerings IPOs General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at